source
- Apnimed upsizes IPO to $192 million to fund launch of oral sleep‑apnea drugApnimed, a Massachusetts‑based biotech, announced an upsized initial public offering that now includes 12 million shares priced at $16 each, generating $192 million in gross proceeds. This amount e…
- Alnylam shares tumble nearly 30% after cutting revenue outlook for key amyloidosis drugsAlnylam Pharmaceuticals saw its market value drop about 30%, roughly $12 billion, after it lowered its revenue forecast for its leading amyloidosis treatments. The company had previously expected…